Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

825 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.
Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, Lakhani SR, Ashworth A. Reis-Filho JS, et al. Among authors: ashworth a. Clin Cancer Res. 2006 Nov 15;12(22):6652-62. doi: 10.1158/1078-0432.CCR-06-1164. Clin Cancer Res. 2006. PMID: 17121884
Synthetic lethal approaches to breast cancer therapy.
Rehman FL, Lord CJ, Ashworth A. Rehman FL, et al. Among authors: ashworth a. Nat Rev Clin Oncol. 2010 Dec;7(12):718-24. doi: 10.1038/nrclinonc.2010.172. Epub 2010 Oct 19. Nat Rev Clin Oncol. 2010. PMID: 20956981 Review.
BRCAness revisited.
Lord CJ, Ashworth A. Lord CJ, et al. Among authors: ashworth a. Nat Rev Cancer. 2016 Feb;16(2):110-20. doi: 10.1038/nrc.2015.21. Epub 2016 Jan 18. Nat Rev Cancer. 2016. PMID: 26775620 Review.
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A. Miller RE, et al. Among authors: ashworth a. Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30. Mol Cancer Ther. 2016. PMID: 27364904
Marked for death: targeting epigenetic changes in cancer.
Pfister SX, Ashworth A. Pfister SX, et al. Among authors: ashworth a. Nat Rev Drug Discov. 2017 Apr;16(4):241-263. doi: 10.1038/nrd.2016.256. Epub 2017 Mar 10. Nat Rev Drug Discov. 2017. PMID: 28280262 Review.
PARP inhibitors: Synthetic lethality in the clinic.
Lord CJ, Ashworth A. Lord CJ, et al. Among authors: ashworth a. Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16. Science. 2017. PMID: 28302823 Free PMC article. Review.
Future cancer research priorities in the USA: a Lancet Oncology Commission.
Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Jaffee EM, et al. Among authors: ashworth a. Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208398 Free PMC article. Review.
825 results